Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
International Paper Drops Buyout Proposal for Smurfit Kappa

2018-06-06 zacks
International Paper Company (IP - Free Report) has decided to cancel its proposal for the takeover of the Irish packaging company — Smurfit Kappa — due to lack of engagement from the latter’s management. Memphis-based International Paper was given time until Jun 6 to make a binding offer for the buyout by the Irish Takeover Panel. The company confirmed that it has dropped its pursuit to acquire its Ireland-based rival.
SEOFF IP INPAP UFS SEOAY SEOJF

4
Domtar Rides on Solid Price Momentum & Cost Optimization

2018-06-04 zacks
On Jun 4, we issued an updated research report on, Domtar Corporation (UFS - Free Report) . The paper & paper products firm continues to benefit from strong price momentum in the Pulp and Paper businesses. Manufactured paper shipments in first-quarter 2018 were 3% higher year over year while average transaction prices for all paper grades increased $3 per ton. Average pulp prices increased $144 per metric ton from the year-ago quarter on solid global demands.
SPPJY SEOFF DB UPMKY UFS SEOAY SEOJF

0
Stora Enso Oyj 2018 Q1 - Results - Earnings Call Slides

2018-04-28 seekingalpha
The following slide deck was published by Stora Enso Oyj in conjunction with their 2018 Q1 earnings call.
SEOFF SEOAY SEOJF

0
DECISIONS OF PONSSE PLC'S ANNUAL GENERAL MEETING

2018-04-09 globenewswire
Financial statements The AGM approved the parent company financial statements and the consolidated financial statements, and members of the Board of Directors and the President and CEO were discharged from liability for the 2017 financial period.
SEOFF SEOAY SEOJF

0
PONSSE OYJ:N VARSINAISEN YHTIÖKOKOUKSEN PÄÄTÖKSIÄ

2018-04-09 globenewswire
Tilinpäätös Yhtiökokous vahvisti emoyhtiön ja konsernin tilinpäätöksen sekä myönsi hallituksen jäsenille ja toimitusjohtajalle vastuuvapauden tilikaudelta 2017.
SEOFF SEOAY SEOJF

5
Reasons Why You Should Hold WestRock in Your Portfolio Now

2018-03-28 zacks
WestRock Company (WRK - Free Report) remains well-poised for growth, backed by its focus on execution of capital allocation strategy and KapStone acquisition. Improving industry conditions and a positive volume along with pricing dynamics are other key growth drivers for the company. However, raw material cost inflation and weak demand for processed foods as well as carbonated drinks remain headwinds.
SEOFF DB VRTV SEOAY WRK SEOJF

1
Domtar Rides on Modest Revenue Growth, Margin Woes Remain

2018-03-26 zacks
On Mar 26, we issued an updated research report on paper & paper products firm, Domtar Corporation (UFS - Free Report) . Domtar is currently seeking growth through profitable investment opportunities with a commitment to pollution-free environment and sustainable practices. The company is also streamlining the cost structure, improving revenue quality and maintaining a healthy cash flow with a disciplined approach to cash utilization.
SEOFF UFS VRTV SEOAY SEOJF

0
Warmer Winters Are a Huge Threat to $30 Billion Nordic Industry - Bloomberg

2018-03-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HLMNY SEOFF SEOAY SEOJF HLHLY HLMNF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...